| Sorafenib in advanced clear-cell renal-cell carcinoma B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Siebels, ... New England Journal of Medicine 356 (2), 125-134, 2007 | 6052 | 2007 |
| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 5970 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4008 | 2018 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3711 | 2008 |
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial B Escudier, A Pluzanska, P Koralewski, A Ravaud, S Bracarda, C Szczylik, ... The Lancet 370 (9605), 2103-2111, 2007 | 2893 | 2007 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ... Annals of Oncology 30 (5), 706-720, 2019 | 1571 | 2019 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1513 | 2010 |
| Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Staehler, ... Journal of clinical oncology 27 (20), 3312-3318, 2009 | 1368 | 2009 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1253 | 2015 |
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial MR Capeding, NH Tran, SRS Hadinegoro, HIHJM Ismail, ... The Lancet 384 (9951), 1358-1365, 2014 | 1137 | 2014 |
| Efficacy and long-term safety of a dengue vaccine in regions of endemic disease SR Hadinegoro, JL Arredondo-García, MR Capeding, C Deseda, ... New England Journal of Medicine 373 (13), 1195-1206, 2015 | 1136 | 2015 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1037 | 2016 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 895 | 2019 |
| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 790 | 2016 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 707 | 2019 |
| A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma C Bertolotto, F Lesueur, S Giuliano, T Strub, M De Lichy, K Bille, P Dessen, ... Nature 480 (7375), 94-98, 2011 | 597 | 2011 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, F Algaba, JJ Patard, V Khoo, T Eisen, ... Annals of oncology 25, iii49-iii56, 2014 | 456 | 2014 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, T Eisen, C Porta, JJ Patard, V Khoo, F Algaba, P Mulders, ... Annals of oncology 23, vii65-vii71, 2012 | 390 | 2012 |
| An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a … C Wood, P Srivastava, R Bukowski, L Lacombe, AI Gorelov, S Gorelov, ... The Lancet 372 (9633), 145-154, 2008 | 386 | 2008 |
| CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ... European urology 72 (6), 962-971, 2017 | 247 | 2017 |
